399 — Innovative Pharmaceutical Biotech Income Statement
0.000.00%
Last trade - 00:00- HK$1.06bn
- HK$2.81bn
- HK$2.09m
Annual income statement for Innovative Pharmaceutical Biotech, fiscal year end - March 31st, HKD millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | HKAS | HKAS | HKAS | HKAS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 15.2 | 11.1 | 8.07 | 6.59 | 2.09 |
| Cost of Revenue | |||||
| Gross Profit | 1.41 | 1.05 | 0.858 | 0.84 | 0.188 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 36.3 | -215 | 28.8 | -310 | 312 |
| Operating Profit | -21.1 | 226 | -20.7 | 317 | -310 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -212 | 36.4 | -255 | 98.7 | -570 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -212 | 36.4 | -255 | 98.7 | -570 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -205 | 45.8 | -246 | 103 | -346 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | -205 | 45.8 | -246 | -20.4 | -346 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.14 | -0.14 | -0.168 | -0.14 | -0.028 |